[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 18, 2016

Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology

Author Affiliations
  • 1Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
  • 2Associate Editor, JAMA
JAMA. 2016;316(15):1541-1542. doi:10.1001/jama.2016.12770

Use of cancer therapies for indications not approved by the US Food and Drug Administration (FDA), also known as “off-label” use, is widely practiced in oncology care.1 Examples include bevacizumab in metastatic esophageal cancer or cetuximab in metastatic prostate cancer. In the United States, off-label use of 10 common cancer drugs accounted for nearly $5 billion in costs in 2010,1 an amount that likely substantially underrepresents current off-label spending given the escalation in oncology drug pricing and number of available products, but recent comprehensive estimates have not been published.

First Page Preview View Large
First page PDF preview
First page PDF preview